

South Carolina Medicaid Pharmacy and Therapeutics Committee
Location: [Virtual Meeting \(Link below\)](#)

<https://scdhhs-events.webex.com/scdhhs-events/onstage/g.php?MTID=e04213e97cd0930b76dc57d90b69a6537>

Wednesday, May 5, 2021 at 4:00p

A G E N D A

- I. WelcomeDr. Edward Behling
Freedom of Information Act/Americans With Disabilities Act Compliance Pledge – This body's official minutes will indicate that this meeting is in compliance with the Freedom of Information Act's mandate that the public be notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.
- II. Approval of Minutes from February 3, 2021 P&T Committee
- III. Public Comment - Drug Classes
 - a. Presenters must pre-register with DHHS no less than seven days in advance of the meeting. Testimony will be limited to three minutes, and there will be only one speaker per pharmaceutical agent under consideration. P&T Committee members may use an additional two minutes to ask the speaker questions, if warranted. **Please e-mail the speaker's name, the product they will discuss, and the CV of the speaker. Additionally, a completed speaker disclosure statement must be faxed to Lisa at 888-656-1239. The form can be found at: <http://southcarolina.fhsc.com/providers/ptcommittee.asp>.** SC Medicaid will need all of this information no later than the close of business April 30, 2021. Emails may be sent to LBCorrell@magellanhealth.com or via fax to Lisa at (888) 656-1239.
 - b. Criteria for Re-Reviews: Previously reviewed therapeutic classes from PDL phases subject to re-review may be opened for re-review if one or more of the following has occurred: a) a new drug in the therapeutic class, b) a new indication for an existing drug in the therapeutic class, c) a new study recognized and generally accepted by the medical community or three peer-reviewed studies for a drug in the therapeutic class.
- IV. Drug Classes for P&T Committee Review P&T Committee
 - Drug Classes for Re-Review**
Androgenic Agents (Transdermal)
Hypoglycemic Incretin Mimetic (GLP1 receptor agonists/combo)(Inj)
Insulins (Inj)
 - Drug Classes for Review**
Anti-Migraine (CGRP Blockers/Modulators)(oral)
Glucagon Agents
- V. Old Business P&T Committee
- VI. New Business P&T Committee
Next P&T Meeting – August 4, 2021

VII. Adjournment